Men syndrome clinical features
Reading File
Finding Sources
Searching PubMed
"multiple endocrine neoplasia" clinical features
Reading File
Reading File
Reading File
Reading File
Here is a detailed breakdown of Multiple Endocrine Neoplasia (MEN) Syndromes based on Robbins & Kumar Pathology and Robbins Cotran & Kumar Pathologic Basis of Disease.
Multiple Endocrine Neoplasia (MEN) Syndromes
General Features (All MEN Types)
These are autosomal dominant disorders with proliferative lesions (hyperplasias, adenomas, carcinomas) in multiple endocrine organs. Compared to sporadic tumors, MEN-associated tumors share these features:
- Occur at a younger age
- Arise in multiple endocrine organs, either synchronously or metachronously
- Are often multifocal even within a single organ
- Are preceded by an asymptomatic hyperplastic stage in the cell of origin
- Are more aggressive and have a higher recurrence rate
MEN-1 (Werner Syndrome)
Gene: MEN1 tumor suppressor gene (chromosome 11q13) - encodes menin, a transcription factor complex component. Germline loss-of-function mutations.
Mnemonic: "3 Ps" - Parathyroid, Pancreas, Pituitary
| Organ | Manifestation | Key Points |
|---|---|---|
| Parathyroid | Primary hyperparathyroidism | Most common feature (80-95% of patients); initial presentation in most; hyperplasia + adenomas; causes hypercalcemia, nephrolithiasis |
| Pancreas | Endocrine (islet cell) tumors | Leading cause of death; aggressive, often metastatic; frequently functional; multiple microadenomas common |
| Pituitary | Prolactinoma (most common); also somatotropinoma | Macroadenoma with hyperprolactinemia; somatotropinoma causes acromegaly |
Pancreatic tumor syndromes in MEN-1:
- Zollinger-Ellison syndrome - gastrinoma - intractable peptic ulcers (duodenum is actually the most common gastrinoma site)
- Hypoglycemia + neurologic features - insulinoma
Additional features beyond the 3 Ps:
- Carcinoid tumors
- Thyroid and adrenocortical adenomas
- Lipomas (skin)
- Duodenal gastrinomas (more common than pancreatic gastrinomas)
MEN-2 (Subclassified into MEN-2A, MEN-2B)
Gene: RET proto-oncogene - encodes a receptor tyrosine kinase. Germline gain-of-function (activating) mutations.
MEN-2A (Sipple Syndrome)
| Organ | Manifestation | Frequency |
|---|---|---|
| Thyroid (C cells) | Medullary thyroid carcinoma (MTC) | ~100% of untreated patients; multifocal; aggressive; secretes calcitonin; preceded by C-cell hyperplasia |
| Adrenal medulla | Pheochromocytoma | 40-50%; often bilateral; may be extra-adrenal; <10% malignant |
| Parathyroid | Hyperplasia - primary hyperparathyroidism | 10-20%; causes hypercalcemia, renal stones |
Variant: Familial medullary thyroid carcinoma (FMTC) - isolated MTC with RET mutations but without other MEN-2A features; older age of onset, more indolent.
MEN-2B (also called MEN-3)
Distinctive mutation: Single amino acid substitution in the tyrosine kinase domain of RET (different from MEN-2A mutations).
| Feature | Details |
|---|---|
| Medullary thyroid carcinoma | Multifocal; more aggressive than MEN-2A |
| Pheochromocytoma | Similar to MEN-2A |
| No primary hyperparathyroidism | Key distinguishing feature from MEN-2A |
| Mucosal neuromas/ganglioneuromas | Lips, tongue, GI tract, eyes, respiratory tract - visible nodules on lips/tongue |
| Marfanoid habitus | Long axial bones, hyperextensible joints, resembles Marfan syndrome |
MEN-4
Gene: CDKN1B - encodes p27 (cell-cycle checkpoint protein). Germline inactivating mutations.
- Phenocopies MEN-1 (parathyroid + pituitary tumors)
- Diagnosed when MEN-1 features are present but MEN1 gene testing is negative
MEN-5 (Newest)
Gene: MAX tumor suppressor gene. Germline mutations.
- Bilateral pheochromocytomas
- Other tumors
- No medullary thyroid carcinoma (distinguishes from MEN-2)
Key Comparison Table
| Feature | MEN-1 | MEN-2A | MEN-2B |
|---|---|---|---|
| Gene | MEN1 (TSG) | RET (proto-oncogene) | RET (proto-oncogene) |
| Mutation type | Loss-of-function | Gain-of-function | Gain-of-function |
| Protein | Menin | RET tyrosine kinase | RET tyrosine kinase |
| Parathyroid | Hyperplasia/adenoma (80-95%) | Hyperplasia (10-20%) | Absent |
| Thyroid | Not characteristic | MTC (~100%) | MTC (~100%, more aggressive) |
| Adrenal | Not characteristic | Pheo (40-50%) | Pheo (~50%) |
| Pancreas | Islet tumors (gastrinoma, insulinoma) | Absent | Absent |
| Pituitary | Prolactinoma, acromegaly | Absent | Absent |
| Neuromas | Absent | Absent | Mucosal neuromas/ganglioneuromas |
| Marfanoid habitus | Absent | Absent | Present |
Clinical Screening & Prevention
-
All patients with medullary thyroid carcinoma should undergo germline RET mutation testing (even apparently sporadic cases may carry germline mutations)
-
RET mutation carriers should have prophylactic thyroidectomy to prevent inevitable MTC development
-
In MEN-2 kindreds, genetic screening replaced annual calcitonin biochemical assays (which had poor sensitivity)
-
Robbins & Kumar Basic Pathology, pp. 3084-3140
-
Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 2905-2949
This is a shared conversation. Sign in to Orris to start your own chat.